|
|
Article: CyDex Pharmaceuticals Presents Phase 2 Clinical Trial Results for Captisol-Enabled[R] Budesonide/Azelastine Combination Solution Nasal Spray at American Academy of Allergy Asthma and Immunology (AAAAI) Meeting.(Clinical report)
- Article from:
- Business Wire
- Article date:
- March 16, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Reports Statistically Significant Results
Company Seeks Commercial Partner
LENEXA, Kan. -- CyDex Pharmaceuticals, Inc. today announced the presentation of Phase 2 clinical trial results of its novel, proprietary Captisol-Enabled([R]) budesonide/azelastine nasal spray (CDX-313) for seasonal allergic rhinitis (SAR). The budesonide/azelastine combination nasal spray demonstrated statistically significant improved results over a nasal spray placebo.
A randomized, double-blind, placebo-controlled, three-way cross-over study was conducted in 108 SAR patients to compare the relative efficacy of Captisol-Enabled Budesonide + Azelastine Nasal Spray ...